How to ease your stress when finding more time is impossible

Every year, millions of people decide to make some sort of behavioral change, most often focused around something in the physical dimension (weight loss, exercise, etc.).

They buy new workout clothes, hire trainers and join clubs — literally hitting the ground running when Jan. 1 arrives. Parking lots of fitness centers throughout the world are packed and there are lines for the treadmill and elliptical. But alas, the regular gym attendees know they only need be patient because by Feb. 1, the parking lots empty, there are a plethora of treadmills and ellipticals available for use and normalcy returns to the club.

What happened?

The holistic you
Every person is a complex, biological being, having physical, emotional, mental and spiritual dimensions.

■  The physical is understood, consisting of exercise, nutrition and sleep, but change seldom happens in human behavior when only considering a diet or a new way to tone one’s abs. It’s the other dimensions of energy that truly impact behavior change and how our behaviors impact others.

■  The emotional dimension is defined by the quality of our energy. In this dimension, people can oscillate between feelings of challenge and threat to feeling energized or fatigued. One can quickly see that leadership in business should be able to create an environment of high-quality emotions. As a snapshot, some leaders can be authoritarian in nature and run their organizations through fear. If an employee feels threatened, they will not be able to access all of their talent and skill on demand. They will often find themselves in survival mode, trying to protect their job instead of freely performing at the highest level possible.

■  The mental dimension is the focus of our energy. Mentally, we live in a scattered world where multitasking is the norm. Being present and laser-focused is difficult in a business culture where we are overscheduled, overcommitted and constantly bombarded with the chimes, dings and vibrations of the various alerts we receive.

■  The spiritual dimension — the most important dimension — is the force of our energy. Human beings are mission-specific. We always have a purpose and it is very difficult to stop us. In business, with distractions and demands, we often find ourselves skimming across the surface of life, unable to delve deeper into reflection or introspection.

I often ask executives, no matter how productive they were last year, if they were asked to do more this year? The answer is always a unanimous “yes.” It appears that year after year we will only be asked to do more and we will never be asked to do less.

So, how will you increase your capacity to meet the never-ending demands in your life? More time is not an option. The answer is to assess your levels of energy in all four dimensions, deciding how you need to live your life to develop more energy, which will allow you to access your talent and skill on demand.

As you develop your New Year’s resolution, think about all four dimensions of energy and how you’re putting them to use in your daily life.

Both your professional and personal life will benefit. ●

Johnson & Johnson beats forecast, but 2013 view lags expectations

NEW BRUNSWICK, N.J., Tue Jan 22, 2013 — Johnson & Johnson reported better-than-expected fourth-quarter earnings on Tuesday, but took another big special charge for its recalled artificial hips and forecast 2013 earnings below Wall Street forecasts.

The diversified healthcare company said it earned $2.6 billion, or 91 cents per share. That compared with $218 million, or 8 cents per share, in the year-ago period when the company took charges of more than $3 billion, including $800 million for medical costs related to recalls of defective “metal-on-metal” hip replacement devices made by its DePuy Orthopedics unit.

J&J on Tuesday said it took special charges of $800 million in the most recent quarter, primarily related to new charges related to the defective artificial hips.

Excluding special items, J&J earned $1.19 per share. Analysts, on average, expected $1.17 per share.

Global revenue rose 8 percent to $17.56 billion, below Wall Street expectations of $17.7 billion.

Sales of prescription drugs jumped 7 percent in the quarter to $6.52 billion, helped by strong sales of its treatments for arthritis, psoriasis and HIV. Sales of medical devices rose almost 14 percent to $7.38 billion, in part due to the company’s recent acquisition of trauma-device maker Synthes.

The company forecast full-year 2013 earnings, excluding special items, of $5.35 to $5.45 per share. Analysts, on average, expected $5.49 per share, according to Thomson Reuters I/B/E/S.

Johnson & Johnson third quarter profit beats view as drug sales rebound

NEW BRUNSWICK, N.J., Tue Oct 16, 2012 – Johnson & Johnson reported better-than-expected quarterly results on Tuesday, as pharmaceutical sales rebounded with the help of newer products, including treatments for prostate cancer and hepatitis C.

The company earned $3.0 billion, or $1.05 per share, in the third quarter, compared with $3.2 billion, or $1.15 per share, in the year-earlier period.

Excluding special items, the diversified healthcare company earned $1.25 per share. Analysts, on average, expected $1.21 per share, according to Thomson Reuters I/B/E/S.

Revenue rose 6.5 percent to $17.1 billion, topping Wall Street expectations of $16.97 billion. Sales would have risen 10.8 percent if not for the stronger dollar, which hurts the value of revenues in overseas markets.

J&J slightly raised its full-year profit forecast to between $5.05 and $5.10 per share from $5.00 to $5.07 per share.

Company shares rose 1.1 percent to $69.40 in premarket trading.

J&J to pay $181 million to settle improper marketing claims

NEW BRUNSWICK, N.J., Thu Aug 30, 2012 –Johnson & Johnson said it has agreed to pay $181 million to resolve consumer fraud claims by 36 U.S. states and the District of Columbia that it improperly marketed its Risperdal antipsychotic drug for unapproved uses.

The diversified healthcare company, which has also been targeted by federal authorities for separate but related criminal allegations, said it had already set aside funds to cover the civil settlement. The funds will be divided among the states participating in the agreement, announced on Thursday.

The company said the settlement was not an admission of wrongdoing.

As lawsuits climb, J&J may have new hip trauma

CHICAGO, Thu Jul 12, 2012 – Johnson & Johnson faces a potentially more damaging and costly sequel to the $3 billion recall of its ASR all-metal artificial hips two years ago, one of the most expensive medical device failures in U.S. history.
A successor to ASR, the Pinnacle metal-on-metal hip system has nearly 1,600 lawsuits pending in U.S. courts. Doctors who are tracking large groups of patients with both products estimate that more than 10 percent of the Pinnacle all-metal hips will have failed in the next two to three years.
Metal-on-metal hip implants were sold on being more durable than those made of other materials, such as polyethylene or ceramic. They are meant to last up to 15 years, but as controversy over all metal-on-metal implants heats up, fewer surgeons are using them.
A survey taken by the American Academy of Orthopaedic Surgeons in 2010 showed 16 percent of surgeons were using metal-on-metal implants before the U.S. Food and Drug Administration warned of potential problems. That number dropped to 10 percent since the FDA warning, and doctors say the number probably has dwindled further.
Many patients with the Pinnacle metal-on-metal device are experiencing the same problems as those who got the ASR product, including pain and swelling, limited mobility, and dislocation. Perhaps most concerning, some doctors say, is the high levels of cobalt and chromium in the bloodstream resulting from wear of the all-metal implants. Metallosis, as it is known, can lead to cardiovascular, neurological, renal and thyroid problems, in addition to destroying soft tissue, muscle and bone.
“We’re simply seeing the tip of the iceberg with metal-on-metal failures,” Dr Mary O’Connor, an orthopedic surgeon at the Mayo Clinic in Jacksonville, Florida, said of the entire class of metal-on-metal devices. O’Connor said she does not use metal-on-metal hip implants because she has been concerned about metal poisoning for years.

Johnson & Johnson quarterly profit beats forecast, but sales lag

NEW BRUNSWICK, Tue Apr 17, 2012 – Johnson & Johnson reported better-than-expected quarterly earnings but global company revenue fell slightly on anemic sales of medical devices and consumer medicines – businesses that have been hit by costly recalls in the past two years.

The diversified healthcare company said it earned $3.91 billion, or $1.41 per share, in the first quarter. That compared with $3.48 billion, or $1.25 per share, in the year-ago period.

Excluding special items, J&J earned $1.37 per share, topping the average analyst forecast of $1.35 per share, compiled by Thomson Reuters I/B/E/S.

Global company revenue slipped 0.2 percent to $16.14 billion, versus Wall Street expectations of $16.26 billion.

Avon names Johnson & Johnson’s Sherilyn McCoy as CEO

NEW YORK, Mon Apr 9, 2012 – Avon Products Inc. said it named Johnson & Johnson executive Sherilyn McCoy as its chief executive officer, effective April 23.

The world’s largest direct seller of cosmetics, which rejected a takeover bid from fragrance company Coty Inc. last week, had announced in December that it would look outside for a new CEO and that current Chairman and CEO Andrea Jung would become executive chairman.

McCoy, 53, was with the pharmaceutical company for three decades, and most recently served as vice chairman of Johnson & Johnson’s pharmaceutical, consumer, corporate office of science and technology, and information technology divisions.

McCoy was promoted to the post of vice chairman at J&J in December 2010, setting her up as a possible successor to CEO William Weldon. But in February, J&J announced that Alex Gorsky, who was named vice chairman at the same time as McCoy, would be the company’s CEO, effective April 26.

McCoy joined J&J in 1982 as a scientist in the company’s personal products unit. She had been in charge of J&J’s pharmaceutical division since 2009 and has held senior management roles in the company’s medical device business.

Since January 2011, McCoy also ran J&J’s consumer products business, which had been besieged by a series of recalls of an array of brands, including Tylenol.

In a statement, Weldon said McCoy “was instrumental in helping to bring stronger strategic focus to our pharmaceutical business as it builds a robust pipeline and launches important new medicines; and to our consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges.”

Buffett says may consider selling J&J stock

OMAHA, Neb. – Berkshire Hathaway Inc. is holding onto its Johnson & Johnson stake for now but may consider selling it, given the company’s recent problems, Berkshire chief Warren Buffett said on Monday.

J&J “obviously has messed up in a lot of ways in the last few years,” Buffett said in a CNBC interview, adding it was not clear why. The healthcare giant has issued a series of massive recalls of products ranging from artificial hips to infant Tylenol.

Buffett said J&J remains an attractive business at its price but would be on his sell list if he needed capital.

Berkshire owned 31.4 million J&J shares as of Dec. 31, about a 1.2 percent stake. Buffett has listed J&J as one of Berkshire’s biggest investments by valuation since 2006.

J&J recently announced that William Weldon will retire as chief executive in April and will be succeeded by Alex Gorsky, currently vice chairman of the Medical Device and Diagnostics Group.

Gorsky will be J&J’s ninth top executive, all of them chosen from inside the company. Some investors say his expertise in medical devices helped him secure the top job, but they question whether yet another insider at the 125-year-old company will be able to make needed changes.

J&J to pay $158 million to settle Texas Risperdal case

AUSTIN, Texas ― Johnson & Johnson said on Thursday it will pay $158 million to settle a Texas lawsuit accusing the drugmaker of improperly marketing its Risperdal anti-psychotic drug to state residents on the Medicaid health program for the poor.

The settlement fully resolves all Risperdal-related claims in Texas, the company said. The agreement is specific to the state of Texas and does not involve any other ongoing state or federal Risperdal litigation.

The deal settles claims brought by Texas in 2004 and involves alleged Medicaid overpayments during the years 1994 to 2008 “and will circumvent potentially lengthy and costly appellate activities,” according to a statement from J&J’s Janssen Pharmaceuticals unit.

The complaint against J&J and several of its units filed in U.S. district court in Texas had alleged that company representatives “targeted every level of the Texas Medicaid Program with misrepresentations about the safety, superiority, efficacy, appropriate uses and cost effectiveness of Risperdal.”

Johnson & Johnson highlights strategies for pharmaceuticals business growth

NEW BRUNSWICK, N.J.― Johnson & Johnson will review growth strategies for its pharmaceuticals business at a meeting with the investment community today.  Senior leaders from the company’s executive committee and pharmaceuticals segment will review how the business plans to address some of the world’s major unmet medical needs and outpace pharmaceutical market growth with an optimized product portfolio, robust pipeline and a demonstrated track record of successful global product launches.

“Our people focus every day on addressing the world’s major unmet medical needs with superior science,” said Vice Chairman, Executive Committee, Sheri McCoy.  “Since our last Pharmaceuticals Business Review with analysts in 2009, we have built a highly productive pharmaceuticals pipeline, with six key new products launching and another two pending regulatory review, some in multiple geographies.”

Johnson & Johnson’s pharmaceuticals business will highlight its plans for continuing to address major medical needs and build on its market leadership in five therapeutic areas: neuroscience; cardiovascular and metabolism; immunology; oncology and infectious diseases/vaccines.

Johnson & Johnson’s pharmaceuticals business generated $22.4 billion in sales last year, 36 percent of the company’s total revenue, and it ranks as the world’s eighth largest pharmaceutical company and fifth largest biotech company.  The pharmaceuticals business saw over 6 percent operational growth in the first quarter of 2011 as new products contributed to growth and core brands delivered solid performance.

Johnson & Johnson’s pharmaceuticals business has taken a disciplined management approach to increasing its efficiency in order to invest in its pipeline and new product launches.  For example, the pharmaceuticals business has seen a significant increase in productivity over the last two years based on the ratio of sales per employee, and it continues investing in R&D at higher rates than its competitive set.